Expanding Global Support: IgA Nephropathy Foundation Launches Go Global Network to Connect and Empower IgAN Patients Worldwide. By expanding our network to Canada, we are building a stronger, more ...

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

Living with the rare condition of IgA nephropathy can feel lonely. Patient advocate Stuart Miller shares his treatment journey and how to stay connected with those who understand. Share on ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...